Industry

DUBLIN–(BUSINESS WIRE)–The “Global Sports Medicine Industry, Forecast to 2028” report has been added to ResearchAndMarkets.com’s offering. This analysis covers innovative devices propelling industry growth as well as market trends and emerging business models that will dominate the sports medicine sector. It highlights the dominating solutions in the sports medicine devices industry, including body reconstruction and … [Read more…]

CHICAGO–(BUSINESS WIRE)–Support Over Stigma received a $5,000 grant from the SBB Research Group Foundation, which awards monthly grants to support impactful organizations. Support Over Stigma (SOS), located in St. Charles, IL, is dedicated to empowering military members, veterans, first responders, and their families through a comprehensive array of support to address mental health and service-related … [Read more…]

The Application is based on Phase 3 CheckMate –9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #CheckMate—Bristol Myers Squibb (NYSE: BMY) today announced that the European Medicines Agency (EMA) validated its Type II variation application for Opdivo® (nivolumab) … [Read more…]

The Lancet publishes data from the pivotal DELTA 1 and DELTA 2 trials, marking the first time an investigational topical pan-Janus kinase (JAK) inhibitor for chronic hand eczema (CHE) has been featured in the journal.1 The DELTA 1 and DELTA 2 trials investigated the safety and efficacy of investigational delgocitinib cream in adult patients with … [Read more…]

– Application based on results from the MOTION Phase 3 study, in which vimseltinib demonstrated statistically significant and clinically meaningful improvement in objective response rate compared to placebo – OSAKA, Japan & WALTHAM, Mass.–(BUSINESS WIRE)–Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the European Medicines Agency (EMA) has accepted … [Read more…]

PALO ALTO, Calif.–(BUSINESS WIRE)–Guardant Health, Inc. (NASDAQ:GH), a pioneer in precision oncology, today announced the appointment of Dr. Manuel Hidalgo Medina to its board of directors, effective immediately. Dr. Hidalgo currently serves as Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and NewYork-Presbyterian/Weill Cornell Medical Center. “Dr. Hidalgo brings a … [Read more…]

SAN FRANCISCO–(BUSINESS WIRE)–Doximity, Inc. (NYSE:DOCS), the leading digital platform for U.S. medical professionals, today announced it will report financial results for its fiscal first quarter ended June 30, 2024 after market close on August 8, 2024. Doximity will host a conference call and webcast at 2:00 p.m. PT (5:00 p.m. ET) to discuss the financial … [Read more…]

Leveraging the Power of the NMDP BioTherapies Cord Blood Bank Alliance, Readily Accessible Cord Blood Units That Meet the Criteria Established in Marin, et al in Nature Medicine for Production of CAR-NK Cells MINNEAPOLIS–(BUSINESS WIRE)–NMDP BioTherapiesSM (formerly known as the Be The Match BioTherapies), a leader in cell and gene therapy development support, and the … [Read more…]

Company to introduce significant product upgrades that enable treating multiple tumors in a single treatment plan to improve patient experience. HAYWARD, Calif.–(BUSINESS WIRE)–#AAPM2024—RefleXion Medical, an external-beam theranostic oncology company, today announced that researchers from multiple clinical programs will present pioneering scientific evidence in 37 oral and poster presentations confirming the efficacy and feasibility of the … [Read more…]

RADNOR, Pa.–(BUSINESS WIRE)–Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that the China National Medical Products Administration (NMPA) has approved ganaxolone oral suspension for the treatment of epileptic seizures in patients two years of age and older with CDKL5 deficiency disorder (CDD). In … [Read more…]